Sign In
Buy APTO
$1.71
+0 (+0%)
At Close: Jul 25, 2025
Aptose to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
04:01pm, Monday, 10'th Apr 2023
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
Aptose Biosciences Announces Q4 And FY 2022 Results
02:20pm, Friday, 24'th Mar 2023
Aptose Biosciences (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced its financ
Aptose Biosciences Inc. (APTO) Q4 2022 Earnings Call Transcript
10:07pm, Thursday, 23'rd Mar 2023
Aptose Biosciences Inc. (NASDAQ:APTO ) Q4 2022 Earnings Conference Call March 23, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
11:44pm, Friday, 10'th Mar 2023 GlobeNewswire Inc.
SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
04:05pm, Thursday, 09'th Mar 2023
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inh
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
07:30am, Thursday, 02'nd Mar 2023
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inh
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
12:30pm, Wednesday, 28'th Dec 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase in
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
07:30am, Wednesday, 28'th Dec 2022
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhi
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
01:42pm, Monday, 12'th Dec 2022 Benzinga
Gainers
Aptevo Therapeutics Inc. (NASDAQ: APVO) shares rose 104% to $7.00 in pre-market trading. Aptevo Therapeutics said 100% clinical benefit rate was achieved in Phase 1b trial evaluating Apvo436
Aptose Biosciences Establishes New At-The-Market Facility
11:15am, Monday, 12'th Dec 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
02:00pm, Sunday, 11'th Dec 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO and NEW ORLEANS, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today provided a clinical update of its lead oral myeloid kin
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
09:05pm, Wednesday, 07'th Dec 2022 GlobeNewswire Inc.
Data to be presented in poster at ASH Annual Meeting Data to be presented in poster at ASH Annual Meeting
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
12:30pm, Monday, 14'th Nov 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targe
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
08:41am, Friday, 04'th Nov 2022 Benzinga
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.
Acutus
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
06:35pm, Thursday, 03'rd Nov 2022 Benzinga
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.
Virax Biolabs Group Limited (NASDAQ: VRAX) surged 34% to $2.25 after the company announced the distribution of a RSV-I
